| 1. |
Assessing the real worth of cholinesterase inhibitors in AD |
| |
PharmacoEconomics & Outcomes News,
Volume &NA;,
Issue 449,
2004,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 2. |
A consensus statement outlining treatment practice recommendations for physicians involved in the early treatment of children and adolescents with attention-deficit hyperactivity disorder (ADHD) or disruptive behavioural disorders has been published |
| |
PharmacoEconomics & Outcomes News,
Volume &NA;,
Issue 449,
2004,
Page 3-3
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 3. |
Patients with diabetes mellitus who demonstrate a high degree of persistence with therapy have lower healthcare costs than those with lower rates of adherence, |
| |
PharmacoEconomics & Outcomes News,
Volume &NA;,
Issue 449,
2004,
Page 5-5
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 4. |
News from the 62nd annual meeting of the AAD |
| |
PharmacoEconomics & Outcomes News,
Volume &NA;,
Issue 449,
2004,
Page 6-7
L Hunt,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 5. |
Ciprofloxacin ER value for money in uncomplicated UTIs |
| |
PharmacoEconomics & Outcomes News,
Volume &NA;,
Issue 449,
2004,
Page 7-7
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 6. |
Cardiac care service use, satisfaction affected by socioeconomic status |
| |
PharmacoEconomics & Outcomes News,
Volume &NA;,
Issue 449,
2004,
Page 8-8
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 7. |
Off-label, unlicensed prescribing common among paediatric patients |
| |
PharmacoEconomics & Outcomes News,
Volume &NA;,
Issue 449,
2004,
Page 9-9
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 8. |
The QoLIAD*is a reliable, practical and valid instrument for measuring the effect of atopic dermatitis, and its treatment, on QOL, |
| |
PharmacoEconomics & Outcomes News,
Volume &NA;,
Issue 449,
2004,
Page 10-10
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 9. |
Total revenues for Serono, the largest biotechnology company in Europe, leapt by 31.3% to > $US2 billion in 2003, |
| |
PharmacoEconomics & Outcomes News,
Volume &NA;,
Issue 449,
2004,
Page 11-11
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2004
数据来源: ADIS
|
首页
